The Unlock Trade: Eat, Drink, and Be Merry

Hey, let’s go for a movie this weekend.
Would you like to join me for a coffee this evening?
Let’s order pizza tonight.
I’ll have a Happy Meal.

As COVID-19 rampaged worldwide, all plans for outdoor engagements had to be dropped. No one imagined there would be no ENTERTAINMENT, ENTERTAINMENT, and ENTERTAINMENT

From lip-smacking burgers to crispy fries to cheesy pizzas, young India hits fast-food joints to satiate their cravings. Most such joints are light on the pocket and high on taste. India’s quick service restaurant (QSR) sector had
a CAGR of 20% over the last five years (up to FY20). The spurt in food delivery aggregators such as Swiggy and Zomato helped QSRs hit a home run and added a new tailwind to the industry. Additionally, the increasing penetration of Internet and smartphone in India boosted growth in the food delivery segment

Click here to read more

RBI’s Monetary Policy Committee Meeting Outcome:

RBI’s Monetary Policy Committee (MPC) keeps the status quo, continues to maintain an accommodative stance until necessary to mitigate the impact of the COVID-19 pandemic. The Marginal Standing Facility (MSF) rate and bank rates remain unchanged at 4.25%. Repo rate remains unchanged at 4%. Reverse repo rate also remains unchanged. Rural demand is expected to remain strong due to the normal monsoon forecast. 

The Real GDP is estimated at 9.5% in FY22, against the earlier forecast of 10.5%. Of this, Q1 is expected to be 18.5% (versus 26.2% forecast earlier), Q2 – 7.9% (8.3%), Q3 – 7.2% (5.4%), Q4 – 6.6% (6.2%). CPI inflation is projected at 5.1% for FY22. On a quarterly basis, CPI for Q1 is likely to be 5.2%, Q2 – 5.4%, Q3 – 4.7%, Q4 – 5.3%.



In May, money aggregates (M3) grew 9.9% y/y and bank credit grew 6% y/y. 

The committee is focussing on turning to equitable distribution of liquidity. It has been adopting a lot of proactive and pre-emptive approaches to revive growth in the economy. It has infused Rs 36,545 crore into the industry. Another operation under government securities 1.0 (G-sec) for Rs 40,000 crore worth of purchase will be conducted. Further, G-SAP 2.0 worth Rs 1.2 lakh crore will be taken in Q2 FY22 to support the market. It is opening a Rs 15,000 crore On-Tap Liquidity Window at a repo rate for contact intensive sectors. This will provide additional lending to the hospitality, bus operators, tourism, salons, aviation ancillary services.

It is also actively engaging in the forex market to strengthen the financial system. The exchange rate is stable despite global spillovers. Forex reserves have risen to $598B.

To support MSMEs, RBI is extending a special liquidity facility of Rs 16,000 crore to SIDBI. Under the Resolution Framework 2.0, the RBI will expand coverage of borrowers in the scheme of borrowers up to Rs 50 crore, from the earlier Rs 25 crore. It decided to permit authorized dealer banks to place margins on behalf of foreign portfolio investors (FPIs), and regional rural banks (RRBs) are now allowed to issue certificates of deposits (CDs) with an option to buy back the CDs. All issuers of CDs will be permitted to buy back their CDs before maturity, on certain conditions.

Recent articles :

Break the Stereotype; Buy High, Sell Higher

SwingTrader India Monthly Big Picture – May 6th 2021

Nifty50 – 14,631.10, lost 0.40% last month

 

 

Last month, the index traded in a range-bound zone, almost in line with our expectations as published in our previous monthly and weekly reports.

 

In April, the index failed to chase its previous two month’s high and turned volatile in the range of 15,044–14,151. The market action in the month formed a Doji candle, with a lower-high and lower-low price formation, and the index settled with a nominal loss of 0.40%. The momentum indicator RSI on the monthly chart was almost flat, and it was hovering around 69–67 levels for the last two months, with a neutral bias from a long-term perspective. Likewise, other technical indicators also suggest a neutral bias from a long-term perspective.

 

On the weekly chart, the index is trading along an upward sloping trendline from the recent multi-year low and trending above all key moving averages. Also, a detailed analysis of the weekly chart indicates the index is volatile and choppy for the last ten weeks, and it has formed multiple DOJI candles in a row on the weekly chart. The weekly RSI is now trending in a negative slope, with a lower trough and peak, and has now breached the trendline connecting the high of August 2018 and January 2020. Additionally, RSI is also now trending below this trendline, indicating a  negative bias. Another trend following indicator, MACD, is trending in a negative slope with a negative crossover. However, weekly MACD is still trending in the positive zone.

 

Likewise, the index has been trading in a downward sloping parallel trendline on the daily chart and is currently trending below its 21- and 50-DMA. An analysis of the daily price action over the last three months indicates the index has formed multiple bearish candlestick patterns on every upward bounce, and every upward bounce has sold off. Though in the last week of April, the index tried to cross its downward sloping trendline but failed to hold above 14,900. And the index once again approached the 100-DMA, which is currently placed around 14,486. Hence, we expect the index to turn more negative, and a fresh downside window may open toward 13,700–13,600 levels once the index decisively breaches these levels.

 

On the derivative data front, for the monthly contracts expiring May 27, the PCR stands at 1.52. Further, monthly option data indicates maximum Call OI stands at 15,000 strikes, which are 35.45 lakh contracts, followed by 21.71 lakh contracts for 15,500 strikes. While the maximum Put OI stands at 14,000 strikes, followed by 13,500, which are 46.58 lakh contracts and 39.73 lakhs contracts, respectively. Further, the strike-specific analysis of Call-Put OI indicates the index may face strong resistance around 15,000 and has strong support around 14,000 followed by 13,500. 

 

Further, as per the O’Neil Methodology of the market direction, the current market is in an “Confirmed Uptrend” with two distribution days in the last 25 trading sessions.

 

Summary

 

All the above-mentioned multi-timeframe technical parameters, along with derivatives data and O’Neil Methodology of market direction, suggest a sideways kind of move in the coming month with negative bias. The last three month’s price action suggests the index is facing strong resistance around 14,900–15,000. Likewise, on the downside, it has support around 14,200–14,100. 

 

Also, the index is still trending in the sideways zone with a negative bias, but the study of various technical indicators, along with market psychology, indicates bulls are losing their grips, and a fall below the 100-DMA may open a fresh downside window toward 14,000 and 13,700–13,600. In short, our bias would remain negative for the current ongoing month until the index is trending below 14,800–14,900. However, it may turn bullish if the index will cross and hold above 14,800- 14,900.

 

FII/ DII Activity for the Last Six Months

 

 

Indian Sectoral Coverage – As per O’Neil Methodology

 

 

Current Status of Major Global Indices – As per O’Neil Methodology

 

 

Sectoral Analysis

 

Bank Nifty 33,781.80, down 1.56% last month

 

This sectoral index started showing negativity from the second half of February and extended its falling momentum in the subsequent months. It lost 1.56% last month and formed a bearish candle, with a lower-high and lower-low price formation. Last month, this space was more volatile than Nifty50 and underperformed the overall market. Momentum indicator RSI on the monthly chart accelerated in a negative slope and is currently placed below 60 levels. Further analysis of the price action from January 2018 in conjunction with RSI on the monthly chart indicates RSI must cross and hold above 65–66 levels for a strong bullish trend in this space. And from a price analysis point of view, the index must hold above 32,400–32,600, which was previously the all-time pivot level. Apart from monthly charts, weekly and daily charts of Bank Nifty are already showing sideways trends with a negativity bias as it has already started trending below the 50-DMA with five distribution days.

 

The multi-timeframe analysis of Bank Nifty indicates a sideways trend with negative bias. A fall below 32,400–32,600 may make the index more volatile in the coming month. However, it may turn out to be positive if the index holds above 32,400–32,600. And on the downside, a sustainable fall below 32,400 may lead it toward 30,000–29,000.

 

Nifty Pharma – 13,507.45, up 10.06% last month

 

The Nifty Pharma index moved as per our expectations and rose toward 13,500 as mentioned in the last monthly report. Currently, Nifty Pharma is trending in bullish territory and trending above all its key moving averages on all time frame charts. The index has ended in positive territory for the last seven consecutive weeks and is trending upward on the weekly chart. Even on the monthly chart, the index has made a big bullish candle with the formation of a higher-top and higher-bottom price structure. The momentum indicator RSI is well-placed in the bullish zone and indicates bullish structure on higher time frame charts. Another indicator MACD is showing positive indication with a positive crossover. From now onwards, we expect our bias to remain positive in this space until the index is holding above 13,500. Further, in our opinion, this index may move towards the 17,000 mark in the next few months.

 

Nifty FMCG – 33,623, down 3.75% last month

 

The index started correcting after hitting its recent all-time high of 35,422 in the first week of April. The market action in the last month formed a bearish candle. Likewise, an analysis of weekly charts during the last five months showed a sideways trend as the index formed a double-top price structure, coupled with RSI divergence and MACD negative crossover. Also, the momentum indicator RSI formed a double-top on the monthly chart, indicating a sideways trend. Likewise, on the daily chart, there is a negative crossover of its 50- and 100-DMA, which again suggests some negativity until the index holding below its 50- and 100-DMA. After considering the above factors, we expect a sideways kind of move in the range of 35,000–31,500 in the coming weeks. From the coming month’s point of view, we expect this index to turn more volatile below 33,400–34,500 levels.

 

Nifty Auto – 9,641, down 2.02% Last month

 

After touching its recent multi-year high of 11,093 on February 9, the index has corrected around 15% and touched the low at 9,345 on April 12. After breaching its 100-DMA with a gap down on April 12, the index has been trying to consolidate for a while and is struggling to move forward. Looking at the current situation and following an analysis of the multi-timeframe chart of this particular index, our bias would remain negative in the next few weeks. We expect this index to retest its 200-DMA in the next few weeks and months, which is 6.8% down from the current level, which is placed around 9,000. From May month’s perspective, our bias would remain negative for this particular sector.

 

Nifty IT – 25,664, down 0.68% last month 

 

This sectoral index moved as per our expectations and touched a high of 25,500 levels, however, profit-booking at higher levels pushed the index down, and it closed with a loss of 0.68% m/m. As a result, it formed an “inverted hammer” candlestick pattern on the monthly chart. Likewise, on the weekly chart, it has formed a spinning-top-like bearish candle formation and is subsequently exhibiting a sideways trend with a negative bias. Also, it has breached the 50-DMA on the daily chart. The multi-timeframe analysis indicates this index may trade sideways with a negative bias in the range of 24,000–27,500 in the next few weeks.

 

Nifty Metal – 4,848, up 21.9% last month

 

As we had mentioned in our last monthly report published on April 6, the metal index continued to show great strength and formed a bullish candle, with a higher-high and higher-low price formation last month. Currently, the index is trending above all its key moving averages with bullish momentum. Technical indicators, RSI and MACD, are trending in an upward slope with a positive crossover on both monthly and weekly charts. The index is currently trending 19.77% above its 50-DMA and 59.69% above its 200-DMA, and our current bias is positive for metals. Over the last few months, the index has gained substantially, but there is no sign of negativity. Though, some profit-booking cannot be denied at current levels. But current trends in this space suggest it may gain further from these levels and may test 5,300 levels in the coming month. Hence we advise our subscribers to follow a cautious approach while taking trades in this space.

 

Nifty Energy – 18,031, down 0.85% last month

 

This sectoral index moved as per our expectations and fell toward 17,150 levels. However, it bounced back sharply from lower levels and ended with a nominal loss of 0.85% last month. The price action on the monthly chart has formed a “hammer” candle pattern. Likewise, it was negative on the weekly chart but turned positive after a gap-up opening in the last week of April. The technical indicator RSI on the monthly chart was trending flat, and on the weekly chart, it was trending in a negative slope. Though, the recovery that took place in the last week of April turned the sentiment in this space. The detailed analysis of this index and stock components of this index indicates that some positive moves may happen in the coming weeks. From now onwards, our bias would remain positive until the index is holding above 17,500. We expect this index may move towards 18,800–18,900 levels in the next few weeks, and trade above these levels may lead it toward 19,400–19,500.

 

Nifty Realty – 309.60, down 7.35% last month

 

The Realty index also moved as per our expectations and touched a low of 298 levels. On the monthly chart, it formed a bearish candle, with a lower-high lower-low price formation. Further, it retested the downward sloping trendline connecting the high of January 2018 to February 2020, and it is currently hovering around that range, i.e., around 300 level. It has also breached its 100-DMA and is now trading between its 100- and 200-DMA with a negative bias. The multi-timeframe price chart, along with technical indicators, indicates some bounce back cannot be denied from the current levels. However, overall sentiment in this space is still showing negative trends, hence, sustainable trading below 300 may open a fresh downside window toward 285 and 270– 265.

 

Related Article:

 

Key Highlights from RBI Governor’s Speech On May 05th 2021

India Fights Back with a Slew of Measures; Conducts a Large Vaccination Program

 

 

Key Highlights from RBI Governor’s Speech On May 05th 2021

  • Small finance banks on-lending to microfinance institutions (MFIs) would be considered as priority sector lending amid the ongoing COVID-19 pandemic till FY22 end.

 

  • Banks are incentivized to lend to weak sectors. They can create a COVID loan book in their balance sheets. An equal amount can be parked at the RBI with 40bps above reverse repo rate.

 

  • To support vaccine manufacturers, medical facilities, hospitals, and patients, on-tap liquidity of Rs 50k crore is set up and is open till FY22 end.

 

  • The second purchase of G-Sec for Rs 35,000 cr under G-SAP 1.0 will be conducted on May 20. G-SAP is contributing to softening of G-Sec yields, and in turn, private sector borrowing in the market.

 

  • Regarding inflation, the governor believes that it may not vary much with the projection made at its April monetary policy committee meeting. Normal monsoon should help contain food price pressures, especially in cereals and pulses. However, the inflation for the year would depend on the COVID restrictions and the impact on supply chains and logistics.

 

  • It also decided to conduct a special three-year long-term repo operation (SLTRO) of Rs 10,000 crore at repo rate for the SFBs. The amount is to be deployed for fresh lending of up to Rs 10 lakh per borrower. This facility will be available till October 31, 2021.

 

  • It announced relaxation in overdraft (OD) facility for state governments. The maximum number of days of OD in a quarter is increased from 36 to 50 days and the number of consecutive days of OD from 14 to 21 days.

 

  • Banks are allowed to utilize 100% of floating provisions/counter-cyclical provisioning buffer held by them as of December 31, 2020, for making specific provisions for NPAs with prior approval of their Boards. Utilization is permitted with immediate effect and up to FY22 end.

 

  • The global economy is exhibiting signs of recovery supported by fiscal and monetary stimulus. But the outlook is highly uncertain and clouded with risks. World merchandise trade has maintained its decent uptrend and global financial markets have regained buoyancy in April on the back of vaccine optimism.

 

Related Article:

India Fights Back with a Slew of Measures; Conducts a Large Vaccination Program

Bajaj Finance Stock Is Nearing its Buy Point

 

India Fights Back with a Slew of Measures; Conducts a Large Vaccination Program

To combat the COVID-19 pandemic, India has started one of the world’s largest vaccination programs. The Government of India has ensured a countrywide reach of the vaccination program, setting up a total of 61,347 sites for the purpose. According to government statistics, 12.3 crore Dose 1 vaccinations and 2.5 crore Dose 2 vaccinations have been administered.

 

Currently, registered applicants are given one of two vaccine variants – either Covishield (90.7%) or Covaxin (9.3%). India has been trying to ramp up the pace of vaccinations to shield the nation from the Coronavirus. Without the imposition of lockdowns, it is a near-impossible to stop the spread of the virus. Another way to stop the spread is vaccination.

 

Following are the three major medical factors that help combat the pandemic: one, the Sputnik V vaccine; second, antiviral drug Molnupiravir, and Zydus Cadila’s phase 3 clinical trials of its own developed COVID-19 vaccine.

 

 

Sputnik V – third vaccine to be used in India

 

Dr Reddy’s Laboratories (Dr Reddy’s) is expecting the first lot of Sputnik V stock from the Russian Direct Investment Fund (RDIF) by end of May 2021. In September 2020, Dr Reddy’s and RDIF partnered to conduct clinical trials of Sputnik V and to obtain rights for the former to distribute the first 100M doses, later increased to 125M doses. Sputnik V was developed by the Gamaleya National Research Institute of Epidemiology and Microbiology. It will be the third vaccine used in India against the coronavirus, after Covishield and Covaxin. It gives around 92% protection against COVID-19, per late-stage trial results published in The Lancet.

 

Sputnik V uses a cold-type virus, engineered to be harmless, as a carrier to deliver a small fragment of the coronavirus to the human body. It safely exposes the body to a part of the virus’s genetic code, thus allowing the
body to recognize the threat and learn to fight it off, without risk of falling ill. After being vaccinated, the body produces antibodies especially tailored to fight the coronavirus. The human immune system is thus primed to
fight the coronavirus when it encounters it for real. One of the major advantages of Sputnik V is that it can be stored at 2–8° Celsius, which makes it easy to transport and store.

 

Molnupiravir – drug that helps treat COVID-19 patients

 

Merck & Co., Inc. (Merck) entered into a non-exclusive licensing agreement with Cipla, Dr Reddy’s Laboratories, Emcure Pharmaceuticals, Hetero Labs, and Sun Pharmaceutical Industries to manufacture and distribute the drug Molnupiravir. This is an investigational oral antiviral drug being studied in a phase 3 trial to treat non-hospitalized COVID-19-infected patients. Per the agreement, these companies are permitted to manufacture, market, and distribute the drug in India and also in more than 100 low- and middle-income countries. Molnupiravir is an investigational potent ribonucleotide analog that inhibits the replication of multiple RNA viruses, including SARS-CoV-2, which causes COVID-19. It has been shown to be active in several models of
SARS-CoV-2, including for prophylaxis, treatment and prevention of transmission, as well as SARS-CoV-1, and Middle Eastern Respiratory Syndrome (MERS).

 

Merck will also donate more than $5M worth of oxygen-production equipment, masks, hand–sanitizers, and financial aid to support India in its fight against the pandemic.

 

Zydus Cadila to launch Virafin injection soon; also conducts phase 3 trials of ZyCoV-D

 

Zydus Cadila announced that its drug, Virafin, received restricted, emergency-use approval from the Drug Controller General of India (DCGI) to treat adult COVID-positive patients presenting moderate symptoms. Antiviral
drug Virafin was earlier used to help treat Hepatitis C before it was repurposed for COVID-19. It is administered as an injection. In clinical trials, phase 2 was conducted with 40 patients who presented moderate COVID-19 symptoms; phase 3 was conducted with 250 patients. According Zydus Cadila, 91.15% of the COVID-positive patients in the phase 3 trial recovered in just seven days after receiving the first dose.

 

Zydus Cadila is also conducting phase 3 clinical trials of its DNA-based vaccine candidate, ZyCoV-D. The company has recruited 28,000 people to have a broader perspective, and has recruited people aged 75+ and children of ages 12–18. It is confident about the vaccine’s safety and efficacy. The first two phases have provided good data on safety and strong data on immunogenicity, comparable to most other vaccines being tried currently.